Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Outline of Final Research Achievements |
In the present study, we demonstrated that the expression of DEC1 and DEC2 was controlled in a pathological stage-dependent manner in human endometrial cancer (HEC). Our in vitro assays showed that DEC1 and DEC2 suppressed tumor cell invasion. DEC1 and DEC2 also suppressed the transcription of the EMT effector, TWIST1. We elucidated that the transcription factor SP1 was involved in the basal transcriptional activity of TWIST1 and that DEC1 and DEC2 competed with SP1 for DNA binding to regulate the gene transcription. We presented these results as a paper (Asanoma et al., 2015).
|